5-HTTLPR genotype and gender, but not chronic fluoxetine administration, are associated with cortical TREK1 protein expression in rhesus macaques

Neuroscience Letters

Volumn 503, Issue 2, 2011, Pages 83-86

  Bogdan, R ^a,b,c   Fitzgibbon, H ^a   Woolverton, W L ^a   Bethea, C L ^d   Iyo, A H ^a   Stockmeier, C A ^a   Kyle, P B ^a   Austin, M C ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c HARVARD UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

5 HTTLPR; Depression; Monkey; Rhesus macaques; Serotonin; SSRI; TREK1; Western blot

Indexed keywords

FLUOXETINE; PROTEIN; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN TRANSPORTER LINKED PROMOTER REGION; TREK1 PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; GENDER; GENOTYPE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHESUS MONKEY;

ALLELES; ANIMALS; BLOTTING, WESTERN; BRAIN CHEMISTRY; CEREBRAL CORTEX; FEMALE; FLUOXETINE; GENOTYPE; MACACA MULATTA; MALE; ORGAN SIZE; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SEX CHARACTERISTICS;

EID: 80052927014     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.08.005     Document Type: Article

References (20)

1. Bennett A.J., Lesch K.P., Heils A., Long J.C., Lorenz J.G., Shoaf S.E., Champoux M., Suomi S.J., Linnoila M.V., Higley J.D. Early experience and serotonin transporter gene variation interact to influence primate CNS function. Mol. Psychiatry 2002, 7:118-122.
2. Bergstrom R.F, Lemberger L., Farid N.A., Wolen R.L. Clinical pharmacology and pharmacokinetics of fluoxetine: a review. Br. J. Psychiatry Suppl. 1988, 47-50.
3. Blardi P., De Lalla A., Leo A., Auteri A., Iapichino S., Di Muro A., Dell'Erba A., Castrogiovanni P. Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients. J. Clin. Psychopharmacol. 2002, 22:131-136.
4. Dillon D.G., Bogdan R., Fagerness J., Holmes A.J., Perlis R.H., Pizzagalli D.A. Variation in TREK1 gene linked to depression-resistant phenotype is associated with potentiated neural responses to rewards in humans. Hum. Brain Mapp. 2010, 31:210-221.
5. Gordon J.A., Hen R. TREKing toward new antidepressants. Nat. Neurosci. 2006, 9:1081-1083.
6. Heurteaux C., Lucas G., Guy N., El Yacoubi M., Thümmler S., Peng X.-D., Noble F., Blondeau N., Widmann C., Borsotto M., Gobbi G., Vaugeois J.-M., Debonnel G., Lazdunski M. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat. Neurosci. 2006, 9:1134-1141.
7. Honoré E. The neuronal background K2P channels: focus on TREK1. Nat. Rev. Neurosci. 2007, 8:251-261.
8. Jans L.A.W., Riedel W.J., Markus C.R., Blokland A. Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. Mol. Psychiatry 2007, 12:522-543.
9. Kennard L.E., Chambley J.R., Ranatunga K.M., Armstrong S.J., Veale E.L., Mathie A. Inhibition of the human two-pore domain postassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. Br. J. Pharmacol. 2005, 144:821-829.
10. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Muller C.R., Hamer D.H., Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274:1527-1531.
11. Liou Y.J, Chen T.J., Tsai S.J., Yu Y.W., Cheng C.Y., Hong C.J. Support for the involvement of the KCNK2 gene in major depressive disorder and response to antidepressant treatment. Pharmacogenet. Genomics 2009, 19:735-741.
12. Mazella J., Petrault O., Lucas G., Deval E., Beraud-Dufour S., Gandin C., El-Yacoubi M., Widmann C., Guyon A., Chevet E., Taouji S., Conductier G., Corinus A., Coppola T., Gobbi G., Nahon J.L., Heurteaux C., Borsotto M. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biol. 2010, 8:e1000355.
13. McCormack K., Newman T.K., Higley J.D., Maestripieri D., Sanchez M.M. Serotonin transporter gene variation, infant abuse, and responsiveness to stress in rhesus macaque mothers and infants. Horm. Behav. 2009, 55:538-547.
14. Perlis R.H, Moorjani P., Fagerness J., Purcell S., Trivedi M.H., Fava M., Rush A.J., Smoller J.W. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR*D study. Neuropsychopharmacology 2008, 33:2810-2819.
15. Sanchez M.M, McCormack K., Grand A.P., Fulks R., Graff A., Maestripieri D. Effects of sex and early maternal abuse on adrenocorticotropin hormone and cortisol responses to the corticotropin-releasing hormone challenge during the first 3 years of life in group-living rhesus monkeys. Dev. Psychopathol. 2010, 22:45.
16. Sandoz G., Bell S.C., Isacoff E.Y. Optical probing of a dynamic membrane interaction that regulates the TREK1 channel. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:2605-2610.
17. Szewczyk B., Albert P.R., Rogaeva A., Fitzgibbon H., May W.L., Rajkowska G., Miguel-Hidalgo J.J., Stockmeier C.A., Woolverton W.L., Kyle P.B., Wang Z., Austin M.C. Decreased expression of Freud-1/CC2D1A, a transcriptional repressor of the 5-HT(1A) receptor, in the prefrontal cortex of subjects with major depression. Int. J. Neuropsychopharmacol. 2010, 13:1089-1101.
18. Tsai S.J. Sipatrigine could have therapeutic potential for major depression and bipolar depression through antagonism of the two-pore-domain K+ channel TREK-1. Med. Hypotheses 2008, 70:548-550.
19. Wilens T.E., Cohen L., Biederman J., Abrams A., Neft D., Faird N., Sinha V. Fluoxetine pharmacokinetics in pediatric patients. J. Clin. Psychopharmacol. 2002, 22:568-575.
20. Xi G., Zhang X., Zhang L., Sui Y., Hui J., Liu S., Wang Y., Li L., Zhang Z. Fluoxetine attenuates the inhibitory effect of glucocorticoid hormones on neurogenesis in vitro via a two-pore domain potassium channel, TREK-1. Psychopharmacology (Berl) 2011, 214:747-759.